Page 6 - Uro_Onco_booklet

Local Data on Chemo-Naïve mCRPC Patients
1
• As per a local study, abiraterone may have inferior efficacy in
chemo-naïve patients with symptomatic disease or short duration of
response to prior ADT (i.e. < 10 months).
• The median overall survival (OS) in the cohort of patients treated with
1
abiraterone (18.1 months) was substantially shorter than that found
2
in the COU-AA-302 study (34.7 months).
• The inferior survival outcome may be due to the inclusion of patients
with higher tumour burden, visceral metastases, or symptomatic
disease. 1

Local Data on Post-Chemo Patients
• The same local study found that the clinical efficacy of abiraterone in
local post-chemo patients was comparable to that seen in
COU-AA-301. 1,2
Local study 1 COU-AA-301 2

Median OS (months) 15.5 15.8
Median PFS (months) 6.4 5.6

OS = overall survival; PFS = progression-free survival
3
• In another local study, abiraterone and cabazitaxel were
significantly associated with increased OS in post-docetaxel
patients with mCRPC.

References: 1. Poon DM, et al. BMC Urol 2016; 16: 12. 2. Ryan CJ, et al. Lancet Oncol 2015; 16: 152-60. 3. Poon
DM, et al. Prostate Int 2015; 3: 51-5.
6